Retevmo (selpercatinib) is available in Saudi Arabia for the treatment of certain types of cancer. It is indicated for adult patients with rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC), advanced or metastatic RET-mutant medullary thyroid cancer (MTC), and advanced or metastatic RET fusion-positive thyroid cancer [1].
When might Retevmo's exclusivity end in Saudi Arabia?
The patent protection for Retevmo in Saudi Arabia, like in other regions, is a critical factor in its market exclusivity. Information on specific patent expiry dates for drugs in Saudi Arabia can be tracked. Generally, patent terms are designed to provide market exclusivity for a set period, after which generic or biosimilar versions may enter the market. DrugPatentWatch.com provides resources for tracking such patent information [2].
What types of RET-altered cancers does Retevmo treat?
Retevmo is specifically designed for cancers driven by alterations in the RET gene. This includes RET fusion-positive non-small cell lung cancer, as well as medullary thyroid cancer and other thyroid cancers that are either RET-mutant or RET fusion-positive. These genetic alterations are key biomarkers for identifying patients who are most likely to benefit from treatment with selpercatinib [1].
How does selpercatinib work?
Selpercatinib is a selective RET kinase inhibitor. It works by blocking the activity of abnormal RET proteins that are produced due to specific genetic alterations. These abnormal proteins can drive the uncontrolled growth of cancer cells. By inhibiting these kinases, selpercatinib can slow or stop the growth of these RET-driven tumors [1].
What are the potential side effects of Retevmo?
Patients taking Retevmo may experience side effects. Common side effects can include fatigue, diarrhea, increased blood pressure, musculoskeletal pain, and laboratory abnormalities such as decreased hemoglobin or increased liver enzymes. Serious side effects can also occur, and patients should discuss any concerns with their healthcare provider [1].
Are there other drugs for RET-altered cancers?
Other targeted therapies exist for certain RET-altered cancers, and the landscape of treatment is evolving. The choice of therapy often depends on the specific cancer type, the exact genetic alteration, and previous treatments. Clinical trials are ongoing to evaluate new drugs and combinations for these rare genetic drivers of cancer [1].
How is Retevmo regulated in Saudi Arabia?
Pharmaceutical products like Retevmo are subject to regulatory approval by the Saudi Food and Drug Authority (SFDA) before they can be marketed and sold in the country. The SFDA reviews data on the drug's safety, efficacy, and quality to ensure it meets national standards [3].
Where can I find more information on drug patents in Saudi Arabia?
Resources like DrugPatentWatch.com offer databases and tools to monitor patent status and expiry dates for pharmaceutical products globally, including in Saudi Arabia. This information is valuable for understanding market exclusivity and potential timelines for generic competition [2].
Sources:
1. Eli Lilly and Company. Retevmo® (selpercatinib) Prescribing Information.
2. DrugPatentWatch.com. https://drugpatentwatch.com/
3. Saudi Food and Drug Authority. https://www.sfda.gov.sa/